Arch Therapeutics, Inc. (ARTH) Stock

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.

Arch Therapeutics, Inc. (ARTH) stock trades at $0.00 with a market capitalization of $444. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.00 and $1.57, and currently trades 100.0% below its 52-week high.

On profitability, Arch Therapeutics, Inc. generates a return on equity (ROE) of 87.50% — well above the market average, a sign of a high-quality business, return on capital employed of 67.19%.

Official website: www.archtherapeutics.com